Ajooni Biotech Limited — Others, 13-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Ajooni Biotech Limited has confirmed that for the quarter ended September 30, 2024, there were no deviations in the utilization of proceeds from its recent Right Issue, which raised ₹42.31 crore. The Audit Committee has reviewed the statement, and it was taken on record by the Board. With ₹20.14 crore remaining unutilized, the company is on track with its funding allocations, which include land acquisition and working capital. This clarity may bolster investor confidence, suggesting a stable financial outlook with no immediate risks regarding fund management.